darunavir (prezista) Report issue

Small molecule Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Darunavir (trade name Prezista) is an orally active bis-furan-sulfonamide inhibitor of human immunodeficiency virus (HIV-1) protease. Darunavir was developed by Tibotec Pharmaceuticals (now Janssen R&D Ireland). Darunavir is indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. The drug is co-administered with low-dose ritonavir and other anti-HIV agents. It is the only antiretroviral that has been registered at two different doses, 800/100 mg once-daily or 600/100 mg twice-daily, allowing its administration throughout the entire course of HIV disease, from naive subjects without any HIV-1 resistance to heavily treatment-experienced subjects with widespread triple-class family resistance.   NCATS

Chemistry

  • SMILES: CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1
  • InChIKey: CJBJHOAVZSMMDJ-HEXNFIEUSA-N
  • Mol. Mass: 547.67
  • ALogP: 2.38
  • ChEMBL Molecules:
    darunavir  
    darunavir ethanolate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2.5841 - $887.2500

Australia

$11.5861 - $15.4481
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

{(1s,2r)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3r,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester | (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate | (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl n-((1s,2r)-1-benzyl-2-hydroxy-3-(n(1)-isobutylsulfanilamido)propyl)carbamate | (3r,3as,6ar)-tetrahydro-2h-furo[2,3-b]furan-3-yl (2s,3r)-4-(4-amino-n-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate | (3r,3as,6ar)-tetrahydro-2h-furo[2,3-b]furan-3-yl (2s,3r)-4-(4-amino-n-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate | darunavir | darunavir / cobicistat | darunavir / cobicistat / emtricitabine / tenofovir alafenamide | darunavir ethanolate | darunavir ethnolate | darunavir hydrate | darunavirum | mc-114 | n-((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1s,2r,5r)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide | prezista | [(s)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((r)-phenylmethyl)-propyl]-carbamic acid (3r,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester | tmc114 | tmc 114 | tmc-114 | tmc41629 | uic-940t

Organizations (153)

Research & Development (142)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (38)

Approved Indications (3)


 

Autoimmune Diseases

HIV Infections

Infections

Experimental Indications - Clinical Trial Phases 1-4 (37)


 

Acquired Immunodeficiency Syndrome (Phase 4)

AIDS Dementia Complex (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 1)

Analgesics, Opioid (Phase 1)

Antiretroviral Therapy, Highly Active (Phase 4)

Asthma (Phase 1)

Asymptomatic Infections (Phase 4)

Atherosclerosis (Phase 2)

Cardiovascular Diseases (Phase 4)

Cognition Disorders (Phase 4)

Contraception (Phase 2)

Coronavirus (Phase 3)

COVID-19 (Phase 4)

Cytomegalovirus Infections (Phase 4)

Drugs, Investigational (Phase 1)

Epstein-Barr Virus Infections (Phase 4)

Healthy Volunteers (Phase 4)

Hepacivirus (Phase 1)

Hepatitis C (Phase 1/Phase 2)

Herpesvirus 8, Human (Phase 4)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV Infections ()

Hyperlipidemias (Phase 4)

Infections (Phase 4)

Infectious Disease Transmission, Vertical (Phase 2)

Insulin Resistance (Phase 1)

Latent Tuberculosis (Phase 1)

Obesity (Phase 4)

Papillomaviridae (Phase 4)

Patient Compliance (Phase 4)

Pharmacokinetics (Phase 1)

Pneumonia, Pneumocystis (Phase 3)

Pregnancy (Phase 3)

Proteinuria (Phase 4)

Tuberculosis (Phase 4)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 199
  • # of Trial Organizations: 142

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue